A Phase 3 study evaluating retatrutide (LY3437943) in participants with obesity or overweight reached its primary completion on April 6, 2026. The trial, which enrolled 2335 participants, is investigating the efficacy and safety of the drug for these conditions.
Background
Retatrutide is being studied for the treatment of obesity and overweight. These conditions are significant public health concerns, often associated with various comorbidities, including knee osteoarthritis and obstructive sleep apnea, which are also being addressed in subsets of this trial.
Trial design
The Phase 3 study (NCT05929066) enrolled 2335 participants with obesity or overweight. The trial's purpose is to evaluate the efficacy and safety of retatrutide compared to placebo. The study design includes subsets of participants who also have knee osteoarthritis (OA) or obstructive sleep apnea (OSA). The main study duration is approximately 89 weeks, involving up to 24 visits. An optional addendum allows approximately 500 participants to continue treatment for an additional 24 weeks.
What this means
The primary completion of this Phase 3 study indicates that the main data collection period for evaluating retatrutide in participants with obesity or overweight has concluded. While this marks a significant milestone in the drug's development, specific efficacy and safety results from the trial (NCT05929066) are not yet available. Clinicians and researchers will await the full publication of these results to understand the potential role of retatrutide in managing these conditions, including its impact on related comorbidities like knee osteoarthritis and obstructive sleep apnea.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05929066, titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight", was updated on April 6, 2026, on clinicaltrials.gov.